NCT03846895

Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)

Completed NA Last updated 7 September 2022

What this trial tests

NA trial testing Microablative Fractional CO2 laser in Overactive Bladder (OAB) in 50 participants. Completed in 15 February 2022.

Timeline

12 May 2018

Primary endpoint
15 September 2021

15 February 2022

Quick facts

Lead sponsor	National and Kapodistrian University of Athens
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	12 May 2018
Primary completion	15 September 2021
Estimated completion	15 February 2022
Sites	1 location across Greece

Drugs / interventions tested

• Microablative Fractional CO2 laser

Conditions studied

• Overactive Bladder (OAB) — all drugs for Overactive Bladder (OAB) →

Sponsor

National and Kapodistrian University of Athens

Who can join

Adults 40 to 75, female only, with Overactive Bladder (OAB). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the clinical efficacy and symptom relief of vaginal fractional CO2 laser treatment in post-menopausal women with Overactive Bladder syndrome(OAB). Post-menopausal women with OAB syndrome who receive β3 adrenergic receptors (mirabegron 50mg) treatment, will be randomized in two groups. Half participants will receive active CO2 laser therapy, while the other half will receive placebo CO2 laser therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Is the Addition of CO<sub>2</sub> Laser to β3-Adrenoceptor Agonist Mirabegron Effective in the Management of Overactive Bladder? Results of a Randomized Controlled Trial.
   Kypriotis K, Prodromidou A, Athanasiou S, Zacharakis D, et al · · 2025 · cited 1× · PMID 40731828 · DOI 10.3390/medicina61071198
2. A Study Protocol of Micro-Ablative Fractional CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome.
   Kypriotis K, Zacharakis D, Kathopoulis N, Diakosavvas M, et al · · 2023 · PMID 38090432 · DOI 10.7759/cureus.48645